Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Another phase III, randomized, open-label, non-inferiority, head-to-head trial, AWARD-6, evaluated dulaglutide (1.5 mg) versus liraglutide (1.8 mg) in patients with T2DM
Novo) #HealthcareGovernance #BoardOversight #GLP1 #Obesity #Retatrutide #EliLilly #Pharma #NACD
These findings add to a growing literature detailing a reduction in alcohol intake after GLP-1 agonist medications
Key Findings More than 450,000 patients were included in the final analysis, with an average age of about 60 years, and about half were female (47%)
US$ 29.09
US$ 20.23
US$ 27.77
